Marginal zone lymphoma

15 trials 5 recruiting MedDRA PT
15 Registered trials
5 Recruiting
12 Unique sponsors
14 Unique IMPs
12 Commercial trials
Drug classes (ATC)
— ATC code not specified 9
L Oncology (ATC L) 5
V Various (ATC V) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
BTK inhibitor 3 substances
Monoclonal antibody (rat) 2 substances
IMiD 2 substances
CAR-T cell therapy 1 substance
Monoclonal antibody (chimeric) 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase III: 3 Phase II: 6 Phase I/II: 1 Phase IV: 1 Phase I: 3 Phase I (First in Human): 1

Filter these 15 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 15 trials

Phase III

3 trials
  • BeOne Medicines AG Commercial
    ZANUBRUTINIB
    2022-502548-12-00 14 countries 2023 n=316
    Recruiting
  • Incyte Corp. Commercial
    LENALIDOMIDE; RITUXIMAB; TAFASITAMAB
    2023-504684-16-00 16 countries 2021 n=345 Orphan
    Ended
  • Pentixapharm AG Commercial
    GALLIUM (68GA), PENTIXAFOR
    2022-500918-25-00 5 countries 2024 n=148
    Ended

Phase II

6 trials
  • AstraZeneca AB Commercial
    CAPIVASERTIB
    2024-516386-36-00 1 country 2022 n=1
    Ended
  • Celgene Corp. Commercial
    LISOCABTAGENE MARALEUCEL
    2024-510966-18-00 6 countries 2024 n=99 Orphan
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB
    2024-511747-25-00 5 countries 2019 n=225 Orphan
    Ended
  • Association International Extranodal Lymphoma Study Group (IELSG) Academic
    IBRUTINIB; RITUXIMAB
    2023-507886-25-00 4 countries 2019 n=178 Orphan
    Ended
  • Association International Extranodal Lymphoma Study Group (IELSG) Academic
    ACALABRUTINIB; TAFASITAMAB
    2024-514122-23-00 2 countries 2021 n=22
    Ended
  • Universitaetsklinikum Ulm AöR Academic
    OBINUTUZUMAB
    2024-517476-38-00 1 country 2018 n=56
    Ended

Phase I/II

1 trial
  • Celgene Corp. Commercial
    GOLCADOMIDE; VALEMETOSTAT TOSILATE
    2024-515690-10-00 4 countries 2019 n=204 Orphan
    Recruiting

Phase IV

1 trial
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IBRUTINIB
    2023-507329-40-00 7 countries 2017 n=125
    Ended

Phase I

3 trials
  • Exscientia AI Limited Commercial
    IMP not specified
    2024-516869-36-00 5 countries 2025 n=101
    Recruiting
  • Miltenyi Biomedicine GmbH Commercial
    AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIGEN RECEPTOR DIRECTED AGAINST CD19
    2024-513334-38-00 1 country 2018 n=49
    Ended
  • Nurix Therapeutics Inc. Commercial
    IMP not specified
    2023-510541-25-00 5 countries 2023 n=250
    Recruiting

Phase I (First in Human)

1 trial
  • BeOne Medicines AG Commercial
    IMP not specified
    2022-502157-33-00 5 countries 2023 n=239
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Celgene Corp. Commercial 2 Phase II, Phase I/II 1
BeOne Medicines AG Commercial 2 Phase III, Phase I (First in Human) 2
Association International Extranodal Lymphoma Study Group (IELSG) Academic 2 Phase II 0
Exscientia AI Limited Commercial 1 Phase I 1
Miltenyi Biomedicine GmbH Commercial 1 Phase I 0
Nurix Therapeutics Inc. Commercial 1 Phase I 1
AstraZeneca AB Commercial 1 Phase II 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase II 0
Incyte Corp. Commercial 1 Phase III 0
Pentixapharm AG Commercial 1 Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase IV 0
Universitaetsklinikum Ulm AöR Academic 1 Phase II 0
New trials by year
2019
3
2021
2
2022
1
2023
3
2024
2
2025
1
← All indication landscapes